BMJ Open

Internet-delivered Cognitive-Behavioral Therapy (iCBT) for Adults with Prolonged Grief Disorder (PGD): A Study Protocol for a Randomized Feasibility Trial

Cintia Tur,1 Daniel Campos,2 Rocio Herrero,3 Sonia Mor,1 Alba López-Montoyo,1 Diana Castilla,3 Soledad Quero 1,4

ABSTRACT

Introduction Grief is an emotional reaction to the loss of a loved one with a natural recovery. Approximately 10% of people who lose a loved one develop prolonged grief disorder (PGD). Internet-based and computer-based interventions (ie, internet-delivered cognitive-behavioral therapy, iCBT) are a cost-effective alternative that makes it possible to reach more people with PGD. The main aim of this study is to assess the feasibility of a new iCBT—called GROw—for PGD. As a secondary objective, the potential effectiveness of GROw will be explored.

Methods and analysis This study is a two-arm feasibility randomised trial. A total of 48 adults with PGD who meet the eligibility criteria will be randomised to the experimental group (iCBT, GROw) or the active control group (face-to-face CBT treatment). The treatment is organised sequentially in eight modules in the iCBT format and 8–10 sessions in the face-to-face format, and both formats have the same therapeutic components. There will be five assessment points with qualitative and quantitative evaluations: screening, baseline, after the intervention, 3-month follow-up and 12-month follow-up. Consistent with the objectives, the measures are related to the feasibility outcomes for the main aim of the study (participant adherence, expectations and satisfaction with the treatment, preferences, alliance and utility) and psychological and mental health outcomes for secondary analyses (symptoms of grief, symptoms of depression, symptoms of anxiety, affectivity, quality of life, work and social adaptation, post-traumatic growth, purpose in life, mindfulness and compassion).

Ethics and dissemination The Ethics Committee of the Universitat Jaume I (Castellón, Spain) granted approval for the study (CD/002/2019). Dissemination will include publications and presentations at national and international conferences.

Trial registration number NCT04462146.

INTRODUCTION

Grief is an emotional reaction to the loss of a loved one with gradual recovery. During the recovery process, intense feelings of regret and longing are considered natural and usually diminish over time.1 Unfortunately, 9.8% of the adult non-psychiatric population who suffer a loss develop prolonged grief disorder (PGD).2 PGD is described by the International Statistical Classification of Diseases and Related Health Problems as a persistent and pervasive grief response characterised by longing for the deceased or persistent preoccupation with the deceased, accompanied by intense emotional pain. In addition, at least 6 months must have elapsed since the death of the loved one to make this diagnosis. Chronically disabling and distressing grieving symptoms are also formally recognised in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as persistent complex bereavement disorder (PCBD) within the category of conditions for further study. PCBD is defined as a severe and persistent grief and mourning reaction.4 The mourning period is not only associated with the risk of developing PGD or PCBD, but it is also associated with the development of

Strengths and limitations of this study

- Participants will be randomly assigned to the experimental group (internet-delivered cognitive-behavioral therapy (iCBT)) or active control group (face-to-face treatment).
- Both short-term and long-term follow-up periods (3 and 12 months) are planned.
- Due to the pandemic situation produced by COVID-19, adaptations in the treatment format in the face-to-face control condition could be made.
- Potential effectiveness of iCBT will be assessed by applying within-group changes, and comparisons between iCBT and face-to-face CBT will not be accomplished.
multiple psychological disorders and other physical and psychological symptoms (eg, panic disorder, physical health problems, sleep disturbances, increased use of medications, increased social and work interference).4–8

In the past decade, several studies have tested different interventions for grief symptoms and PGD: cognitive–behavioural therapies (CBTs),9–16 expressive writing therapies,17–19 group interventions (eg, see works20–22), and mindfulness and compassion-based interventions.23–24 Results from a recent meta-analysis show that psychological interventions are effective for reducing grief symptoms in bereaved adults.25

However, most people in need of treatment do not receive any services.26 The existence of effective psychological treatments does not ensure that these treatments reach the people who need them.27 Different ways of administering treatments are needed to improve their dissemination and reach a larger number of underserved people.26–27 Less than 50% of the people who need treatment receive it, even in high-income countries.26,28 Therefore, internet-based and computer-based interventions are becoming increasingly popular. These interventions involve greater access to care and less stigma, compared with visiting mental health clinics.29–30 They are cost-effective and often cheaper than face-to-face interventions.31 Meta-analytic evidence has shown that internet-based interventions are effective, showing evidence of greater effects compared with control groups, and they are as effective as face-to-face psychotherapy (eg, see previous works30–33). Particularly, internet-delivered cognitive–behavioural therapy (iCBTs) belongs to the internet-based and computer-based intervention category. In iCBTs, patients log into a secure website to access, read and download online materials organised in a series of lessons or modules.34 iCBTs are the most widely researched treatment models provided by the internet, and more than 200 randomised controlled trials (RCTs) have been published about them.34 iCBTs have been shown to be clinically effective compared with controls,30 and they have a lower rate of negative symptom results than control conditions.34

In addition, COVID-19 has made PGD a major public health concern worldwide.41 The pandemic has produced widespread implementation of social distancing and visitor restrictions in healthcare centres, thus complicating grief problems.42–45 Recent evidence has pointed out that mental and physical health problems can emerge if the needs of people who experience the loss of a loved one are not addressed.44 To our knowledge, evidence-based treatments delivered through internet for PGD are not widely available. Therefore, it is vital to promote the development and dissemination of internet-based PGD treatments, and telecommunication-based alternatives are proposed as important components for supporting bereaved people.45,46

To date, there are several internet-based and computer-based interventions for the treatment and prevention of grief symptoms and PGD (eg, see previous works45–47), with promising results in reducing symptoms associated with grief.48 These studies have used treatment through email45,47,49 or an online platform.46,50–52 Despite this, few studies have tested iCBT for PGD. There are some studies on the feasibility, acceptance and usability of traditional face-to-face treatments (eg, see previous works35–36), but almost none focus on internet-based and computer-based interventions. Related to this, we found the study by Schladitz et al.,57 which evaluates the user acceptance of an internet-based self-help programme for grief and loss in elderly people, showing high user acceptance of the programme. As far as we know, none of these studies, whether feasibility studies or RCTs, has been tested in the Spanish population. For these reasons, an iCBT for PGD—called GROw—was originally developed for the Spanish-speaking population.

**Objectives**

The main aim of this study is to investigate the feasibility of an iCBT for people with PGD—GROw—compared with a face-to-face intervention for PGD. Specifically, the objectives are (1) to explore patients views of GROw as a treatment for PGD; (2) to evaluate the expectations and preferences of the treatment in both formats, GROw and face-to-face; (3) to investigate patients’ views of the materials and the study design; (4) to assess the satisfaction and acceptability of the treatment; (5) to assess if we can recruit the target population; (6) to explore whether the assessment is too burdensome; (7) to estimate the rate of recruitment and retention to inform the large-scale RCT. Additionally, as a secondary objective the potential effectiveness of GROw will be explored, this is defined as the intragroup changes of symptoms related to PGD from baseline to post-test and follow-ups, and with baseline–post-test being the main comparison.

**METHOD**

**Study design and procedure**

This study is a two-arm randomised trial testing the feasibility of an iCBT for PGD. The diagnosis of PGD will be based on an interview following the criteria of the ICD-1158 and a score >25 on the 19-item inventory of CG (ICG).59–60 Participants who meet the eligibility criteria will be randomly assigned to one of two groups: (1) experimental group (iCBT: GROw); and (2) active control group (face-to-face treatment applied by a therapist). The waiting list control group has already been used in several studies of internet interventions for PGD (eg, see previous works46,47,52). For this reason, and to increase the quality of this study, and based on feasibility questions to design future large studies, an active control group will be used. The informed consent form will be signed before randomisation. Five assessment points will be included: diagnosis and inclusion/exclusion criteria (screening), baseline (t1), immediately after the intervention (t2), 3-month follow-up (t3) and 12-month follow-up (t4). In order to promote participant retention in the
treatment and complete follow-up periods, reminders emails will be sent during treatment (eg, to enter the web platform or attend the face-to-face session) and follow-ups. The study was registered in the clinicaltrials.gov database (NCT04462146, 8 July 2020) and will be conducted following the extension of the Consolidated Standards of Reporting Trials (CONSORT) statement for pilot and feasibility studies, the Consolidated Standards of Reporting Trials of Electronic and Mobile Health Applications and online TeleHealth guidelines, and the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.

Participants

Eligibility criteria

To participate in the study, participants will meet the following inclusion criteria: (1) age ≥18 years; (2) having a total score of ≥25 on the 19-item inventory of CG (ICG) and meeting diagnostic criteria for PGD according to the ICD-11; (3) ability to understand and read Spanish; (4) ability to use a computer and having access to the internet; (5) having an email address; and (6) signing an informed consent. Exclusion criteria are as follows: (1) presence of risk of suicide or self-destructive behaviours; (2) presence of another severe mental disorder (ie, substance abuse or dependence, psychotic disorder, dementia or bipolar disorder); (3) presence of severe personality disorder (eg, borderline personality disorder, obsessive-compulsive personality disorder); (4) presence of a medical condition whose severity or characteristics prevent participation in treatment; (5) receiving another psychological treatment during the study; (6) an increase and/or change in the medication during the study period. The medication is evaluated at baseline (t1), after the intervention (t2), at 3-month follow-up (t3) and at 12-month follow-up (t4). Any increase and/or change in the medication during the study period will imply the participant’s exclusion from subsequent analyses.

Sample size

Based on an estimated number of dropouts of 30%65–67 and considering that the secondary objective is to explore the potential effectiveness defined as the pretest–post-test improvement of symptoms related to PGD, a minimum of 48 participants (24 per group) will be sufficient for the within-group t-test to detect a medium effect size (Cohen’s d=0.50)68 with a power of 0.80 and an alpha of 0.05. The effect size was defined as the pretest–post-test mean change divided by the SD of change scores. In a review of 50 meta-analyses on the effectiveness of psychological interventions,69 integrated their average effect sizes, finding a median value of d=0.75. In place of using this estimate to determine the sample size, and with the purpose of obtaining a more demanding sample size, Cohen’s recommendation for a medium effect size of d=0.50 was assumed. G*Power V.3 software was used to perform power analysis calculations.

Recruitment and screening

Recruitment will be conducted using professional social networks (ie, LinkedIn) and non-professional social networks (eg, Facebook and Instagram). The study will be announced on the Universitat Jaume I website and other media (eg, local newspapers and radio). Posters will be placed in different nearby places (Universitat Jaume I and Universitat de València). In addition, patients who attend the Emotional Disorders Clinic at Universitat Jaume I may be recruited.

People interested in the study may request participation via email or telephone directed to the specific account/number associated with the project, and an experienced therapist will conduct a telephone assessment to determine whether the inclusion and exclusion criteria are met. During this call, interested participants will also be informed of the study conditions (duration, specific characteristics, etc). After accepting the terms and signing the informed consent, the participants will be randomised, using EPIDAT V.4.2, to the experimental group or active control group by an independent researcher. Participants will be informed of the assigned treatment by phone call. All of them will complete the same evaluation (screening, t1, t2, t3 and t4) through a specific online platform (https://psicologiaytecnologia.labpsitec.es/) and phone call interviews. Participants will access the study voluntarily, and they will not receive financial compensation for participating.

Intervention

Therapeutic components

Both groups will receive the same therapeutic content, but applied in different formats. The treatment is organised sequentially in eight modules in the online format and 8–10 sessions in the face-to-face format (see table 1). The main therapeutic components are as follows: motivation for change, psychoeducation, behavioural activation, exposure, mindfulness and compassion strategies, integration and restoration of loss, cognitive reappraisal and relapse prevention. This is an adapted version of the original intervention protocol for complicated grief developed by Botella et al.71 This protocol was based on Neimeyer’s programme, which fosters meaning reconstruction in complicated grief (CG)72 73 and includes elements of the Foa and Rothbaum74 programme for treating trauma-like symptoms and Linehan’s75 guidelines for mindfulness strategies. In updating this treatment, elements of the intervention developed by Shear,76 which has shown efficacy in different controlled studies,14–16 have been included. This intervention is based on the dual-process model of coping with bereavement,77 which identifies two types of stressors, loss-oriented and restoration-oriented, and proposes that adaptive coping is composed of confrontation-avoidance of loss and restoration stressors. Specific elements (ie, cognitive reappraisal) of other computerised psychological treatments for grief have also been included (eg, see previous works77 76 78).

Tur C, et al. BMJ Open 2021;11:e046477. doi:10.1136/bmjopen-2020-046477
the treatment contains new mindfulness activities and compassion and self-compassion strategies.79–84

**iCBT for PGD (GROw)**

This individual self-applied programme is accessible online via https://psicologiaytecnologia.labpsitec.es, a website designed by Labpsitec (Laboratory of Psychology and Technology, Universitat Jaume I, and Universitat de València). Participants will receive a username and password sent to their email address, and they will have access to one 60-minute module per week, although modules 4–6 may take 2 weeks due to their difficulty. The treatment will last 8–10 weeks. The programme contains texts, videos, photos, diagrams, interactive exercises, and downloadable pdfs and audios (see figure 1). Participants can also log in at any time to review content, see the calendar where the session record appears and view their progress through visual graphs (ie, measures of grief, anxiety, depression, and positive and negative affect). A weekly support call from a trained clinician will be made (maximum 10 min) in order to (1) review and reinforce participants’ effort and achievements, (2) motivate them to continue to work on the programme content, and (3) clarify any doubts about the use and functioning of GROw. Patients will receive up to 10 phone calls over a period of 8–10 weeks, and so they will have a maximum of 100 min of therapeutic support. No additional clinical content will be released during the phone calls.

**Individual face-to-face treatment for PGD**

This treatment will be carried out face-to-face by a trained clinician with a master’s degree in clinical psychology and specific training in the treatment of grief. The participant will receive materials about meditation audios and annexes with records and templates to complete the exercises. The sessions will take place at the Emotional Disorders Clinic at Universitat Jaume I in Castellón and Valencia (Spain) or in nearby centres and associations (eg, Valencia or Alicante). Each session will last approximately 60 min. There will be weekly individual sessions, and the content from 4 to 6 sessions could require 2 weeks

**Table 1 Specific objectives and therapeutic contents of the intervention**

| Module/Session | Objective | Content |
|----------------|-----------|---------|
| 1. Welcome module: Starting the programme | Present the treatment | General explanation of treatment |
| | Increase motivation and adherence | Presentation of grief cases as an example |
| | Introduce strategy to manage stress and anxiety | Motivation for change |
| | | Slow breathing technique |
| 2. Understanding reactions to loss | Information about the grieving process and PGD | Psychoeducation |
| | Increase adaptive activities | Behavioural activation |
| | Become aware of grief | Grief self-monitoring diary |
| 3. Coping with loss | Recognise and accept emotional experiences | Mindfulness |
| | Exposure to loss-related objects and situations | Exposure hierarchy |
| 4. Loss integration and restoration: First steps | Integration and restoration of loss by writing | Giving a metaphorical meaning to loss |
| | | Loss diary: Chapter 1, life before loss |
| 5. Deepening integration and restoration of loss | Integration and restoration of loss by writing | Loss diary: Chapter 2, reaction to the death |
| | Contemplating the death from a different perspective | Cognitive reappraisal |
| | Develop a realistic and complete picture of the deceased | Questions about positive and negative aspects and memories of the deceased |
| 6. Consolidating loss integration and restoration | Integration and restoration of loss by writing | Loss diary: Chapter 3, life after loss |
| | | Imaginary conversations with the deceased |
| 7. Self-care, guilt and forgiveness in the grieving process | Working on compassion in grief | Psychoeducation about compassion |
| | Working on the emotion of guilt | The compassionate gesture and phrases |
| | Working on forgiveness | Compassionate coping with difficulties |
| | | Psychoeducation and strategies about guilt |
| | | Psychoeducation and exercise for forgiveness (optional) |
| 8. Evaluating progress and looking to the future | Achievements review | Review of the therapeutic achievements |
| | Anticipate future problems | Action plan for high-risk situations |
| | Reflect on the coping process | Action plan to face difficult dates |
| | | Letter of projection towards the future |

PGD, prolonged grief disorder.
due to its difficulty. The treatment lasts up to 8–10 weeks. No weekly support call will be provided.

**Outcome measures**

A clinical team of mental health professionals with extensive experience in diagnosing and treating stress-related disorders will oversee all the cases. Some questionnaires will be self-administered online through the virtual platform used in the intervention (https://psicologiaytecnologia.labsitec.es), and other questionnaires/interviews will be administered by phone. Participants in both groups (GROw and face-to-face) will have the same evaluation format. Participants and researchers will receive email reminders of each assessment. Table 2 provides an overview of the measurements used, each timepoint, administration type and group.

**Demographics, screening and diagnostic measures**

Demographics will include age, sex, educational level, occupation, civil status, place of residence and influence of situations stemming from the health crisis caused by COVID-19 (confinements, care situations, nearby infections, related deaths, etc), if applicable.

A semistructured interview developed for this study will be used to assess some inclusion/exclusion criteria (eg, internet access, email, etc).

For the diagnosis, two specific PGD assessment instruments will be used: The Inventory of Complicated Grief (IGC), which rates current feelings of grief and differentiates between normal and pathological grief. A total score of >25 is needed because this score indicates complicated grief in people who lost a loved one 6 months ago or more, and it has been adapted specifically for this study by translating it into the Spanish language following a back-translation procedure. The clinical team may consider using the Structured Clinical Interview for DSM-IV (SCID-I) in some cases in order to make the differential diagnosis and ensure that the inclusion/exclusion criteria are met. At the end of the interview, the clinician will assess the level of distress-interference in functioning (from 0 ‘Absent’ to 8 ‘Very severely disturbing/disabling’) using the ADIS (Anxiety Disorders Interview Schedule) clinician’s severity rating scale. A clinical team of mental health professionals with extensive experience in diagnosing and treating stress-related disorders will oversee all cases.

**Primary outcomes: measures of feasibility**

Participant adherence (ie, attrition and dropout percentages) will be assessed in both groups. Moreover, the number of sessions/modules completed will be counted. In addition, the iCBT format (GROw) will record how many times participants enter the modules, how much time they spend on each one and whether they review the content of the modules.

Participants’ acceptance will be assessed with Expectations and Satisfaction Questionnaires adapted from Borkovec and Nau, usability with the Usability and Acceptance Questionnaire and alliance with the Working Alliance Inventory (WAI), adapted from Horvath and Greenberg for online self-administered treatments.

Finally, a semistructured opinion interview with quantitative and qualitative questions was specifically developed.
| Measures                                              | Assessment point | Assessment source | Group       |
|------------------------------------------------------|------------------|-------------------|-------------|
| Sociodemographic data                                | Screening        | Phone interview   | GROw        |
|                                                      |                  |                   | Face-to-face|
| Semistructured interview about inclusion/exclusion   | Screening        | Phone interview   | GROw        |
| criteria                                             |                  |                   | Face-to-face|
| SCI-GC                                               | Screening, t2, t3, t4 | Phone interview   | GROw        |
|                                                      |                  |                   | Face-to-face|
| SCID-I                                               | Screening        | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| ADIS clinician's severity rating scale               | screening, t2, t3, t4 | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| ICG                                                  | Screening, t1, t2, t3, t4 | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| BDI-II                                               | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| TBQ                                                  | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| OASIS                                                | t1, POSTm/s, t2, t3, t4 | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| ODSIS                                                | t1, POSTm/s, t2, t3, t4 | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| PANAS                                                | t1, POSTm/s, t2, t3, t4 | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| QLI                                                  | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| WSAS                                                 | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| PTGI                                                 | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| PIL-10                                               | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| FFMQ-15                                              | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| SCS-SF                                               | t1, t2, t3, t4   | Web               | GROw        |
|                                                      |                  |                   | Face-to-face|
| Expectations and Satisfaction Questionnaires         | t1, t2           | Phone interview   | GROw        |
|                                                      |                  |                   | Face-to-face|
| Usability and Acceptance Questionnaire               | t2               | Web               | GROw        |
|                                                      |                  |                   |              |
| WAI                                                  | t2               | Web               | GROw        |
| Semistructured opinion interview                     |                  |                   |              |
| ► Preferences                                        | t1, t2           | Phone interview   | GROw        |
|                                                      |                  |                   | Face-to-face|
| ► Usefulness of content                              | t1, t2           | Phone interview   | GROw        |
|                                                      |                  |                   | Face-to-face|
| ► Usefulness of each element of the web              | t2               | Phone interview   | GROw        |
|                                                      |                  |                   | Face-to-face|

ADIS, Anxiety Disorders Interview Schedule; BDI-II, Beck Depression Inventory—Second Edition; FFMQ-15, Five-Facet Mindfulness Questionnaire; GROw, Grief-Online, internet-based self-applied treatment for PGD; ICG, Inventory of Complicated Grief; OASIS, Overall Anxiety Severity and Impairment Scale; ODSIS, Overall Depression Severity and Impairment Scale; PANAS, Positive and Negative Affect Schedule; PIL-10, Purpose-In-Life Test; POSTm/s, post module/session; PTGI, Post-traumatic Growth Inventory; QLI, Quality of Life Index; SCID-I, Structured Clinical Interview for DSM-IV; SCI-GC, Structured Clinical Interview for Complicated Grief; SCS-SF, Self-Compassion Scale Short Form; t1, baseline; t2, immediately after the intervention; t3, 3-month follow-up; t4, 12-month follow-up; WSAS, Work and Social Adjustment Scale.
for this study. It includes (1) a 5-point questionnaire that assesses treatment preferences (GROW vs face-to-face) and opinions about which treatment is the most useful, logical, aversive and recommended; (2) a list of 14 points (eg, motivation to change, mindfulness, exposure) about the usefulness of each content (assessed from 0; not at all useful to 10; maximum usefulness); (3) a list of 4 points (text, video, audio and images) about the usefulness of each part of the iCBT format (from 0; not useful at all to 10; maximum usefulness); (4) three semistructured questions on satisfaction, usefulness and adherence on a scale from 0 (not at all) to 10 (very much), with an open question about the reason for the score; (5) an open question about adverse or unexpected effects in the iCBT group; (6) an open question about adverse or unexpected effects due to the health crisis produced by COVID-19; and (7) two semistructured questions about the acceptance of the evaluation procedure and the materials used (from 0; not burdensome at all to 10; extremely burdensome).

Psychological and mental health outcomes
Grief symptoms will be assessed using the Inventory of Complicated Grief (ICG) and depression symptoms will be assessed using the Beck Depression Inventory—Second Edition (BDI-II). To assess the maladaptive thinking common in people with complicated grief, the Typical Beliefs Questionnaire (TBQ) will be used. The Overall Anxiety Severity and Impairment Scale (OASIS) and the Overall Depression Severity and Impairment Scale (ODSS) will be used to assess the frequency and severity of anxiety and depression, respectively. Two independent dimensions of affectivity (PA: positive affect; NA: negative affect) will be assessed using the Positive and Negative Affect Schedule (PANAS). To assess health-rated quality of life, the Quality of Life Index (QLI) will be used. The Work and Social Adjustment Scale (WSAS) will be used to assess psychosocial functional impairment. Post-trauma growth and self-improvement will be assessed using the Posttraumatic Growth Inventory (PTGI). The Purpose-In-Life Test (PIL-10) will be used to assess the personal experience of meaning in life. The Five-Facet Mindfulness Questionnaire (FFMQ-15) and the Self-Compassion Scale-Short Form (SCS-SF) will be used to assess the ability to be aware in experiencing the moment and the capacity for self-compassion, respectively.

Statistical analysis plan
As the main aim of this study is related to the feasibility, the main data will be reported narratively illustrated with descriptive statistics using the CONSORT 2010 statement to guide for reporting this information. Attrition and dropout rates will be calculated using the missing data. In the experimental group, the number of times each patient uses the programme will be used as the measure of adherence. In the active control group, the number of times each patient attends a face-to-face treatment session will be used as the measure of adherence. The summary of the data will be presented as a mean (DS) or frequency (%). As a secondary objective, potential effectiveness of iCBT will be assessed by applying within-group t-tests between the baseline and post-test and follow-ups. In addition, effect sizes and their respective 95% CI for intragroup changes will be reported. Comparisons between iCBT and face-to-face CBT will not be accomplished. These statistical analyses will be conducted for completers and intent-to-treat data. Statistical analyses will be accomplished with the program SPSS V.25.0.

Patient and public involvement statement
There was no involvement in the design and development of the study by patients or the public. The results will be communicated to the patients involved through an end-of-study report by email. The public will participate in the dissemination of the research.

ETHICS AND DISSEMINATION
The protocol for this study was approved by the Ethical Committee of the Universitat Jaume I (Castellón, Spain) (06 March 2019) (file number CD/002/2019). The informed consent of each participant will be explained and required in the initial phone call. Before giving their informed consent, the researchers will inform participants about the study and the possibility of leaving at any stage. Written consent will be obtained before starting the intervention. The study will be conducted in compliance with the Declaration of Helsinki and good clinical practice and current EU and Spanish legislation on privacy and data protection (Spanish Organic Law 3/2018 of 5 December on the Protection of Personal Data and Guarantee of Digital Rights). Most of the questionnaires will be administered from the web https://psicologiaytecnologialabsites. Each participant will have a unique username-password combination to access the site. All data will be protected according to AES (Advanced Encryption Standard) polynomial m(x)=8x+4x+3+x+1 and stored on secure servers at the Universitat Jaume I separately from personal information, using codes. To protect the participants’ privacy, all participant identification information will be replaced by a randomly assigned code. An isolated list will link the numerical codes with the names of the participants. This list and the information obtained from the phone calls will be stored in a locked file cabinet located inside a room with an electronic lock that records access (person, day and time). Only researchers directly involved in the current study will have access to these data. Dissemination will include publications in open access journals with impact factor indexed in Journal Citation Reports (JCR) and presentations at national and international conferences. An end-of-study report of the results of this study will be developed and sent to all participants by mail.

DISCUSSION
The main aim of this study is to investigate the feasibility of an iCBT for people with PGD—GROW—compared with a face-to-face intervention for PGD. Specifically, we want to investigate the opinion of the participants about the
treatment, the study design, the materials used and the evaluation process, and also to assess dropout rates and evaluate if we can recruit the target population to carry out a large-scale RCT in the future. In contrast to other psychological disorders, few studies have evaluated the acceptability and feasibility of this type of treatment and there are few studies focused on the efficacy of internet-based and computer-based interventions for PGD (eg, see previous works\textsuperscript{45–47}), and almost none of them have focused on iCBT.\textsuperscript{46} 50–52

The current situation, due to the COVID-19 pandemic, has made PGD a major public health problem worldwide.\textsuperscript{41} Increased PGD rates are expected\textsuperscript{41} due to different factors, such as (1) the inability to perform proper grief rituals that can have significant positive outcomes for people experiencing a loss (such as attending a funeral)\textsuperscript{111}; (2) the possible feeling that the loved one’s death was distressing and not peaceful\textsuperscript{112}; (3) widespread implementation of social distancing and visitor restrictions in health centres\textsuperscript{42} 43; and (4) the fact that disasters with many victims produce higher levels of grief symptoms.\textsuperscript{41}

Therefore, psychological treatments for PGD are necessary, but the existence of these treatments does not ensure that they reach the people who need them.\textsuperscript{27} The current situation states a new challenge, the restrictions in terms of mobility, access to the traditional healthcare system is at least more difficult than usual, given the overburden of the system due to the pandemic situation, and the potential increased risk of exposure for attending to the healthcare system. Moreover, the challenges that society will face concerning the pandemic in the near future is at least unknown, but not very promising. Therefore, internet interventions could be a potential solution to overcome the current situation and to reach more people in need. In addition to that, it is well stated that internet provides greater access to care, less stigma compared with visiting mental health clinics, and the ability to avoid specific obstacles to diagnosis or treatment, such as when social anxiety keeps the patient from leaving home.\textsuperscript{29} In addition, there is no need for a therapy room, a lesson/module can be repeated,\textsuperscript{113} and they are cost-effective,\textsuperscript{114} and often cheaper than face-to-face interventions.\textsuperscript{31}

As far as we know, GROw is the first iCBT for PGD created in the Spanish language, and it could reach many Spanish-speaking countries as a psychological treatment to care for people with PGD, who represent about 10% of people who have suffered a loss of a loved one\textsuperscript{3} and is becoming a major public health concern worldwide due to the COVID-19.\textsuperscript{41}

GROw has been developed based on larger and more recent studies on the treatment of PGD (eg, see previous works\textsuperscript{15} 16 47). It includes both evidence-based traditional therapeutic components for PGD and more innovative ones, such as mindfulness and compassion strategies. In addition, delivery will be guided, including a weekly phone call from a trained therapist, which has been shown to be more effective than unguided iCBTs.\textsuperscript{115} 116

We expect that iCBT—GROw—will be feasible in order to carry out a large-scale RCT to determine the efficacy and effectiveness of GROw as a treatment for adult patients with PGD.

Trial limitations
First, due to the pandemic situation caused by COVID-19 and related to the mobility restrictions, it is possible that the participants assigned to the face-to-face group will not be able to attend the sessions in person. For this reason, changes and adaptations could be made in the control group treatment application format (eg, conduct video-conferencing sessions). These adaptations would be taken into consideration for the future large-scale RCT. Second, high dropout rates are expected (30%) according to the literature.\textsuperscript{65–67} For this reason, dropout rates have been taken into account in the sample size considerations. Finally, for the secondary aim of this feasibility randomised trial, conclusions will be limited to exploring its potential effectiveness in terms of intragroup changes (changes from baseline to post-intervention and follow-ups), with baseline–post-test being the main comparison, without considering between-group comparisons.

Contributors The manuscript was drafted by CT with important contributions from SQ, D Campos and RH, who provided extensive comments/editing to improve the manuscript. SQ, D Campos, CT, SM, AL-M, and RH developed the contents of the iCBT for PGD, and the treatment was adapted to the online platform by CT, D Castilla and RH. All authors participated in the review and revision of the manuscript and approved the final manuscript for publication.

Funding This work was funded by the 2018 Research Promotion Plan of the Universitat Jaume I (UJA-2018-57). This work has been supported partially by Spanish Ministerio de Ciencia, Innovación y Universidades (Programa Estatal I+D+i, RTI2018-100093-B-I00); plan to promote research at Universitat Jaume I for 2018 (PREDOC/2018/45) and CIBEROBN, an initiative of the ISCIII (ISC III CB06 03/0052).

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Soledad Quero http://orcid.org/0000-0002-8973-1250

REFERENCES
1 Jordan AH, Litz BT. Prolonged grief disorder: diagnostic, assessment, and treatment considerations. Prof Psychol 2014;45:180–7 https://doi.org/10.1037/h0110906
2 Lundorff M, Holmgren H, Zachariae R, et al. Prevalence of prolonged grief disorder in adult bereavement: a systematic review and meta-analysis. J Affect Disord 2017;212:138–49.
3 World Health Organization. International statistical classification of diseases and related health problems, 11th edn, 2019. https://icd.who.int/en
4 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Arlington, VA: American Psychiatric Publishing, 2013. https://psychiatryonline.org/doi/10.1176/apprc.2013.05.01

Tur C, et al. BMJ Open 2021;11:e046477. doi:10.1136/bmjopen-2020-046477
5 Keyes KM, Pratt C, Galea S, et al. The burden of loss: unexpected death of a loved one and psychiatric disorders across the life course in a national study. Am J Psychiatry 2014;171:864–71.
6 Stroebel M, Schut H, Stroebel W. Health outcomes of bereavement. Lancet 2007;370:760–73.
7 Simon NM, Shear KM, Thompson EH, et al. The prevalence and correlates of psychiatric comorbidity in individuals with complicated grief. Compr Psychol 2007;48:395–9.
8 Lancel M, Stroebel M, Eisma MC. Sleep disturbances in bereavement: a systematic review. In: Sleep medicine reviews. W.B. Saunders Ltd, 2020: 53. 101331.
9 Barbosa V, Sá M, Carlos Rocha J. Randomised controlled trial of a cognitive narrative intervention for complicated grief in widowhood. Aging Ment Health 2014;18:354–62.
10 Boelen PA, de Koster J, van den Hout MA, et al. Treatment of complicated grief: a comparison between cognitive-behavioral therapy and supportive counseling. J Consult Clin Psychol 2007;75:277–84.
11 Bryant RA, Kenny L, Josceline A, et al. Treating prolonged grief disorder: a randomized clinical trial. JAMA Psychiatry 2014;71:1329–32.
12 Papa A, Sewell MT, Garrison-Diehn C, et al. A randomized open trial assessing the feasibility of behavioral activation for pathological grief responding. Behav Ther 2013;44:639–50.
13 Rozen R, Popham K, Kotova N, et al. Efficacy of an outpatient treatment for prolonged grief disorder: a randomized controlled clinical trial. J Affect Disord 2014;167:56–63.
14 Shear K, Frank E, Houck PR, et al. Treatment of complicated grief: a randomized controlled trial. JAMA 2005;293:2601–8.
15 Shear MK, Wan J, Shritskaya N, et al. Treatment of complicated grief in elderly persons: a randomized clinical trial. JAMA Psychiatry 2014;71:1287–95.
16 Shear MK, Reynolds CF, Simon NM, et al. Optimizing treatment of complicated grief: a randomized clinical trial. JAMA Psychiatry 2016;73:685–90.
17 O’Connor M, Nikolletti S, Kristjanson LJ, et al. Writing therapy for the bereaved: evaluation of an intervention. J Palliat Med 2003;6:195–204.
18 Range LM, Kovac SH, Marion MS. Does writing about the bereavement lessen grief following sudden, unintentional death? Death Stud 2000;24:115–34.
19 Kovac SH, Range LM. Writing projects: lessening undergraduates’ unique suicidal bereavement. Suicide Life Threat Behav 2000;30:50–60.
20 Constantine RE, Sekula UK, Rubinstein EN. Group intervention for widowed survivors of suicide. Suicide Life Threat Behav 2001;31:428–41.
21 Lieberman MA, Yalom I. Brief group psychotherapy for the spousally bereaved: a controlled study. Int J Group Psychother 1992;42:117–32.
22 Sikkema KJ, Hansen NB, Kochan A, et al. Outcomes from a randomized controlled trial of a group intervention for HIV positive men and women coping with AIDS-related loss and bereavement. Death Stud 2004;28:187–209.
23 Huang F-Y, Hsu A-L, Hsu L-M, et al. Mindfulness improves emotion regulation and executive control on bereaved individuals: an fMRI study. Front Hum Neurosci 2012;18:541.
24 Alonso-Llacer L, Martin PB, Ramos-Campos M. Mindfulness and grief: the mated program mindfulness for the acceptance of pain and emotions in grief. Psicooncologia 2020;17:105–16.
25 Johannsen M, Damholdt MF, Zachariae R, et al. Psychological interventions for grief in adults: a systematic review and meta-analysis of randomized controlled trials. J Affect Disord 2019;253:89–96.
26 Kazdin AE. Evidence-based psychosocial treatment: advances, surprises, and needed shifts in foci. Cogn Behav Pract 2016;23:426–30.
27 Kazdin AE. Evidence-Based Psychotherapies I: changes in models of treatment and treatment delivery. S Afr J Psychol 2015;45:3–21.
28 Chisholm D, Sweeney K, Sheehan P, et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis. Lancet Psychiatry 2016;3:345–24.
29 Aboujaoude E, Salame W, Naim L. Telereental health: a status update. World Psychiatry 2015;14:222–30.
30 Andersson G, Titov N, Dear BF, et al. Internet-delivered psychological treatments: from innovation to implementation. World Psychiatry 2019;18:20–8.
31 Musiat P, Tarrier N. Collateral outcomes in e-mental health: a systematic review of the evidence of added benefits of computerized cognitive behavior therapy interventions for mental health. Psychol Med 2014;44:3137–50.
32 Andersson G, Cuijpers P, Carbring P, et al. Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis. World Psychiatry 2014;13:288–95.
33 Andrews G, Basu H, Cuijpers P, et al. Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: an updated meta-analysis. J Anxiety Disorder 2018;55:70–8.
34 Carbring P, Andersson G, Cuijpers P, et al. Internet-Based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. Cogn Behav Ther 2018;47:1–18.
35 Lewis C, Roberts NP, Simon N, et al. Internet-Delivered cognitive behavioral therapy for post-traumatic stress disorder: systematic review and meta-analysis. Acta Psychiatr Scand 2019;140:66–82.
36 Sijbrandij M, Kunovski I, Cuijpers P. Effectiveness of Internet-delivered cognitive behavioral therapy for posttraumatic stress disorder: a systematic review and meta-analysis. Depress Anxiety 2016;33:783–91.
37 Lange A, van de Ven J-P, Schrieken B. Interapy: treatment of post-traumatic stress via the Internet. Cogn Behav Ther 2003;32:110–24.
38 Andersson G. Using the Internet to provide cognitive behaviour therapy. Behav Res Ther 2009;47:175–80.
39 Andersson G, Carbring P. Hadjistavropoulos HD. Internet-Based Cognitive Behavior Therapy. In: The Science of Cognitive Behavioral Therapy [Internet]. Elsevier. 2017; S131–49, https://linkinghub.elsevier.com/retrieve/pii/B9780128034576000210
40 Karyotakis E, Kemmerlen L, Ripper H, et al. Is self-guided Internet-based cognitive behavioral therapy (ICBT) harmful? An individual participant data meta-analysis. Psychotherapy Research 2018;28:187–205.
41 Eisma MC, Boelen PA, Lenferink LM. Prolonged grief disorder following the coronavirus (COVID-19) pandemic. Psychiatry Res 2020;288:113031.
42 Nyatanga B. Impact of COVID-19 on loss and grief: a personal lens. Br J Community Nurs 2020;25:306–7.
43 Wallace CL, Wladkowski SP, Gibson A, et al. Grief during the COVID-19 pandemic: considerations for palliative care providers. J Pain Symptom Manage 2020;60:e70–6.
44 Kang L, Ma S, Chen M, et al. Impact on mental health and perceptions of psychological care among medical nursing staff in Wuhan during the 2019 novel coronavirus disease outbreak: a cross-sectional study. Brain Behav Immun 2020;87:11–17.
45 Eisma MC, Boelen PA, van den Bout J. Internet-Based exposure and behavioral activation for complicated grief and Ruminating: a randomized controlled trial. Behav Ther 2015;46:729–48.
46 Litz BT, Schorr Y, Delaney E, et al. A randomized controlled trial of an Internet-based therapist-assisted indicated preventive intervention for prolonged grief disorder. Behav Res Ther 2014;61:23–34.
47 Wagner B, Knaevelsrud C, Maercker A. Internet-Based cognitive-behavioral therapy for complicated grief: a randomized controlled trial. Depress Dis 2018;39:1609–19.
48 Tur C, Campos D, Quran S. Internet-Based psychological treatments for grief: review of literature. Rev Argentina Clínica Psicológica 2019;XXVIII:884–900.
49 van der Houwen K, Schut H, van den Bout J, et al. The efficacy of a brief Internet-based self-help intervention for the bereaved. Behav Res Ther 2010;48:359–67.
50 Dominick SA, Irvine AB, Beaucamp P, et al. An Internet tool to normalize grief. Omega 2010;60:71–87.
51 Kersting A, Dölemeyer R, Steining J, et al. Brief Internet-based intervention reduces posttraumatic stress and prolonged grief in parents after the loss of a child during pregnancy: a randomized controlled trial. Psychother Psychosom 2013;82:237–241.
52 Brodbeck J, Berger T, Znoj HJ. An Internet-based self-help intervention for older adults after marital bereavement, separation or divorce: study protocol for a randomized controlled trial. Trials 2017;18.
53 Greenwald N, Barrera M, Neville A, et al. Feasibility of group intervention for bereaved siblings after pediatric cancer death. J Psychosoc Oncol 2017;35:220–38.
54 Holtland L, Duckett W, Teacher U, et al. Developing and pilot-testing a finding balance intervention for older abused bereaved family caregivers: a randomized feasibility trial. Eur J Oncol Nurs 2016;21:66–74.
55 Patel SR, Cole A, Little V, et al. Acceptability, feasibility and outcome of a screening programme for complicated grief in integrated primary and behavioural health care clinics. Fam Pract 2019;36:125–31.
Scocco P, Zerbinati L, Preti A, et al. Mindfulness-based weekend retreats for people bereaved by suicide (PANTA Rhe): a pilot feasibility study. *Psychol Psychother* 2019;92:39–56.

Schlitz K, Förster F, Lübner M, et al. [Grief and loss in elderly people: A qualitative study regarding user acceptance of an internet-based self-help program from user and expert perspective]. *Z Evid Fortbild Qual Gesundwesen* 2020;150-152:112–2.

World Health Organization. *International classification of diseases, 11th revision (ICD-11)*, 2019.

Prigerson HG, Maciejewski PK, Reynolds CF, et al. Inventory of complicated grief: a scale to measure maladaptive symptoms of loss. *Psychiatry Res* 1995;59:65–79.

Limonen Garcia J, Lacasta Reverte M, Garcia García J. Adaptación al castellano del inventario de duelo complicado. Med psic平·tica 2009;16:291–7.

Elridge SM, Chan CL, Campbell MJ, et al. Consort 2010 statement: extension to randomised pilot and feasibility trials. *BMJ* 2016;355:i5238.

Eysenbach G. CONSORT-HEALTH Group. CONSORT-HEALTH: improving and standardizing evaluation reports of web-based and mobile health interventions. *J Med Internet Res* 2011;13:e126.

Chan A-W, Tetzlaff JM, Gotzsche PC, et al. Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.

Chan A-W, Tetzlaff JM, Altman DG, et al. Spirit 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;158:200–7.

Andrews G, Cuijpers P, Craske MG, et al. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. *PloS One* 2010;5:e13196.

van Ballegooijen W, van de Velde E, Arends M, et al. Adherence to Internet-based and face-to-face cognitive behavioural therapy for depression: a meta-analysis. *PloS One* 2014;9:e100674.

Bachmaier I, Mo C, Cuijpers P, et al. A guided internet-delivered intervention for adjustment disorders: a randomized controlled trial. *Clin Psychol Psychother* 2021;28:1–12.

Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Erlbaum, 1988.

Rubio-Aparicio M, Marin-Martinez F, Sanchez-Meca J, et al. A methodological review of meta-analyses of the effectiveness of clinical psychology treatments. *Behav Res Methods* 2018;50:2057–73.

Faull F, Erdfelder E, Lang A-G, et al. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 2007;39:175–91.

Botella C, Osma J, Pálicos AG, et al. Treatment of complicated grief using virtual reality: a case report. *Death Stud* 2008;32:674–92.

Neimeyer RA. Meaning reconstruction & the experience of loss. Washington, DC: American Psychological Association, 2000; 2000.

Neimeyer RA. Meaning reconstruction & the experience of loss. Washington, DC: American Psychological Association, 2001: 359.

Foa E, Rothbaum B. *Treating the trauma of rape: cognitive-behavioral therapy for PTSD*. Guilford Press, 1998. https://psycnet.apa.org/record/1997-36867-000.

Linehan M. *Diagnosis and treatment of mental disorders*. Cognitive-behavioral treatment of borderline personality disorder. Guilford Press, 1993. https://psycnet.apa.org/record/1993-97864-000.

Shear MK. *Complicated grief treatment. Bereavement Care 2015*.

Stroebe M, Schut H. The dual process model of coping with bereavement: rationale and description. *Death Stud* 1999;23:197–224.

Hoffmann R, Große J, Nagl M, et al. Internet-based grief therapy for bereaved individuals after loss due to haematological cancer: study protocol of a randomised controlled trial. *BMJ Cancer Psychiatry* 2018;18.

Camps D, Navarro-Gil M, Herrera-Mercadal P. Feasibility of Internet Attachment-Based compassion therapy (iABC) in the general population: study protocol (Preprint). *JMIR Res Protoc* 2019;8:e13601.

Lopez-Montoyo A, Quero S, Montero-Marín J, et al. Effectiveness of a brief psychological mindfulness-based intervention for the treatment of depression in primary care: study protocol for a randomized controlled clinical trial. *BMC Psychiatry* 2019;19:301.

Navarro-Gil M, Lopez-del-Hoyo Y, Bedia-Alarcon M, et al. Effects of Attachment-Based compassion therapy (ABC) on Self-compassion and attachment style in healthy people. *Mindfulness* 2020;11:51–62.

García-Campayo J, Navarro-Gil M, Demarzo M. Attachment-based compassion therapy. *Mindfulness* 2016;1:88–74.

Javier G-C. La práctica de la compasión: Amabilidad Con Los demás Y Con uno mismo. In: *ILUS books Siglantana*, 2019. http://www.siglantana.com/editorial/la-practica-de-la-compasion-amabilidad-con-los-demases-y-uno-mismo/
107 García-Alandalte Joaquín, Rosa Martínez E, Selles Nohales P, et al. Estructura factorial y consistencia interna de una versión española del Purpose-In-Life test. *Univ Psychol* 2013;12:517–30.

108 Á A-M, Masluk B, Montero-Marín J. Validation of five facets mindfulness questionnaire – short form, in Spanish, general health care services patients sample: prediction of depression through mindfulness scale. *PLoS One* 2019;14:1–17.

109 Raes F, Pommier E, Neff KD, et al. Construction and factorial validation of a short form of the Self-Compassion scale. *Clin Psychol Psychother* 2011;18:250–5.

110 García-Campayo J, Navarro-Gil M, Andrés E, et al. Validation of the Spanish versions of the long (26 items) and short (12 items) forms of the Self-Compassion scale (scs). *Health Qual Life Outcomes* 2014;12:4–9.

111 Castle J, Phillips WL. Grief rituals: aspects that facilitate adjustment to bereavement. *Journal of Loss and Trauma* 2003;8:41–71.

112 Lobb EA, Kristjanson LJ, Aoun SM, et al. Predictors of complicated grief: a systematic review of empirical studies. *Death Stud* 2010;34:673–98.

113 Andersson G, Titov N, Dear BF, et al. Internet-Delivered psychological treatments: from innovation to implementation. *World Psychiatry* 2019;18:20–8.

114 Donker T, Blankers M, Hedman E, et al. Economic evaluations of internet interventions for mental health: a systematic review. *Psychol Med* 2015;45:3357–76.

115 Baumeister H, Reichler L, Munzinger M, et al. The impact of guidance on Internet-based mental health interventions — a systematic review. *Internet Interv* 2014;1:205–15.

116 Cuijpers P, Noma H, Karyotaki E, et al. Effectiveness and acceptability of cognitive behavior therapy delivery formats in adults with depression: a network meta-analysis. *JAMA Psychiatry* 2019;76:700–7.